FGF21 and metabolic disease: The current study aimed to investigate the changes in circulating BDNF and FGF21 with weight reduction and the alleviation of metabolic diseases in morbidly obese patients with or without T2DM 6 months after LSG and the associations between these two neurotrophic factors and clinical variables before and after LSG.